Enhertu 100mg Injection

Enhertu 100 mg Injection – Fam-Trastuzumab Deruxtecan for HER2-Expressing Cancers

Enhertu 100 mg Injection contains Fam-Trastuzumab Deruxtecan-nxki 100 mg, a prescription antibody-drug conjugate used in the treatment of selected HER2-positive, HER2-low, HER2-ultralow, or HER2-mutated cancers. It is supplied as a lyophilized powder in a single-dose vial that must be reconstituted and diluted before intravenous administration. Enhertu combines a HER2-targeting monoclonal antibody with a topoisomerase inhibitor. The antibody attaches to HER2 receptors present on certain cancer cells and delivers the anticancer component into the cells, where it damages their DNA and helps slow or stop their growth. Enhertu may be prescribed for eligible adults with certain forms of breast cancer, HER2-mutated non-small cell lung cancer, HER2-positive gastric or gastroesophageal junction cancer, and selected HER2-positive solid tumors. Patient eligibility must be determined through appropriate HER2 or mutation testing.

Key Features

• Contains Fam-Trastuzumab Deruxtecan-nxki 100 mg: A HER2-directed antibody-drug conjugate.
• Targeted Anticancer Therapy: Delivers an anticancer agent directly to HER2-expressing cells.
• Used for Selected HER2-Related Cancers: Prescribed according to cancer type, HER2 status, and previous treatment.
• Single-Dose Vial: Supplied as a preservative-free lyophilized powder for reconstitution.
• Hospital Administration: Must be administered by trained healthcare professionals through intravenous infusion.

Active Ingredient

• Fam-Trastuzumab Deruxtecan-nxki 100 mg: A HER2-directed antibody-drug conjugate containing a monoclonal antibody linked to a topoisomerase I inhibitor.

Uses

• Certain HER2-positive early or metastatic breast cancers.
• Certain HER2-low or HER2-ultralow unresectable or metastatic breast cancers.
• Unresectable or metastatic non-small cell lung cancer with an activating HER2 mutation after previous systemic therapy.
• Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer after prior trastuzumab-based therapy.
• Selected unresectable or metastatic HER2-positive solid tumors after previous systemic treatment when no satisfactory alternatives are available.

How to Use

• Enhertu must be prescribed and administered by an oncologist or trained healthcare professional.
• It is given only as an intravenous infusion after proper reconstitution and dilution.
• It must not be administered as an intravenous push or bolus injection.
• The dose is calculated according to body weight, cancer type, treatment response, and tolerability.
• Antiemetic medicines may be administered before treatment to help prevent nausea and vomiting.
• Do not substitute Enhertu with trastuzumab or ado-trastuzumab emtansine.

Monitoring and Precautions

• Lung function and respiratory symptoms must be monitored throughout treatment.
• Complete blood counts should be checked before treatment and before each dose.
• Heart function, including left ventricular ejection fraction, should be assessed before and during treatment.
• Inform your doctor if you have lung disease, breathing problems, heart disease, liver problems, kidney impairment, or an active infection.
• Inform your healthcare provider about all prescription medicines, supplements, and other cancer treatments you receive.
• Pregnancy status should be verified before starting treatment.
• Women and men of reproductive potential should use effective contraception for the period recommended by their oncologist.

Warning

• Serious Lung Toxicity: Enhertu may cause interstitial lung disease or pneumonitis, including severe or fatal cases.
• Report cough, fever, breathing difficulty, chest tightness, wheezing, or new or worsening respiratory symptoms immediately.
• It may cause neutropenia and increase susceptibility to serious infections.
• It may affect heart function and may cause left ventricular dysfunction or congestive heart failure.
• Enhertu can cause harm to an unborn baby and should not be used during pregnancy unless specifically directed by a specialist.
• Breastfeeding is not recommended during treatment and for the period specified after the final dose.
• Enhertu is classified as a hazardous medicine and requires specialized handling and disposal.

Common Side Effects

• Nausea and vomiting.
• Fatigue or weakness.
• Reduced appetite.
• Hair loss.
• Constipation or diarrhea.
• Muscle, bone, or joint pain.
• Reduced white blood cells, red blood cells, or platelets.
• Changes in liver enzymes or electrolyte levels.

Storage

• Store unopened vials in a refrigerator between 2°C and 8°C.
• Keep the vial in its original carton to protect it from light.
• Do not freeze.
• Do not shake the vial or prepared solution.
• Preparation, temporary storage, handling, and disposal must be performed by trained healthcare professionals.
• Keep out of reach of children and unauthorized individuals.

Legal Disclaimer: Enhertu 100 mg Injection is a prescription anticancer medicine intended for administration only under the supervision of a qualified oncologist. It may cause serious or life-threatening adverse reactions and requires regular clinical and laboratory monitoring. This information is provided for educational purposes only and should not replace professional medical advice, diagnosis, treatment, or the official prescribing information.